Integumen PLC - Labskin launches remote clinical skin trials
AIM share code: SKIN
24 July 2020
("Integumen" or "Company")
Labskin launches remote clinical skin trials
Virtual skin platform for disease diagnostics to offer individual skincare testing
Labskin, a subsidiary of Integumen, is pleased to announce the launch of the world's first remote clincal skin trials platform. By harvesting the microbiome of a human volunteer's skin, transporting it to the Labskin laboratory to be transplanted onto laboratory-grown skin, it creates an exact replica of the human volunteer's skin microflora - without them leaving their home.
Rinocloud software and AI division, another Integumen subsidiary, built a remote clinical skin trial platform; one that allows trials to happen ethically, efficiently with all protocols being followed and distantly controlled; where all data collected is stored according to the strictest of GDPR guidelines; and critically swabbing can be done under supervision in the human volunteer's own home - so no in-person contact is needed.
Labskin and Rinocloud together created the platform as an extensión to the Labskin AI virtual disease modeling development program that has already transformed the Integumen business model over the last 24 months. The platform is anchored in Labskin technology's ability to harvest and replicate a human subject's microbiome.
"With the spread of COVID-19 continuing to accelerate globally, the science and AI teams advanced this development over the last 3 monhts to create a virtual Clinical Research platform that has been disrupted by the lockdown. This has increased access to immune-suppressed, aged or infirm human volunteers without placing them at risk. It is being further adapted to undertake skin trials for individual consumers for cosmetic, skin disease diagnostics."
I look forward to updating the market very soon on progress with Integumen and other COVID-19 related programmes"
| || |
+44 (0) 7340 055 648
| || |
+44 (0) 1203 368 3550
| || || |
+44 (0) 20 3657 0050
Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
This information is provided by RNS, the news service of the
Quick facts: Integumen
Market Cap: £56.03 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE